Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 2
1987 1
1991 2
1994 2
1998 1
2000 1
2001 1
2002 2
2003 3
2004 2
2006 1
2007 1
2008 5
2009 3
2010 7
2011 5
2012 9
2013 16
2014 15
2015 13
2016 24
2017 27
2018 39
2019 14
2020 15
2021 5
Text availability
Article attribute
Article type
Publication date

Search Results

199 results
Results by year
Filters applied: . Clear all
Page 1
Remdesivir and COVID-19.
Wang LY, Cui JJ, Ouyang QY, Zhan Y, Guo CX, Yin JY. Wang LY, et al. Among authors: cui jj. Lancet. 2020 Oct 3;396(10256):953-954. doi: 10.1016/S0140-6736(20)32019-5. Lancet. 2020. PMID: 33010833 Free PMC article. No abstract available.
MASS SPECTROMETRY-BASED PERSONALIZED DRUG THERAPY.
Cui JJ, Wang LY, Tan ZR, Zhou HH, Zhan X, Yin JY. Cui JJ, et al. Mass Spectrom Rev. 2020 Sep;39(5-6):523-552. doi: 10.1002/mas.21620. Epub 2020 Jan 5. Mass Spectrom Rev. 2020. PMID: 31904155 Review.
Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations.
Drilon A, Ou SI, Cho BC, Kim DW, Lee J, Lin JJ, Zhu VW, Ahn MJ, Camidge DR, Nguyen J, Zhai D, Deng W, Huang Z, Rogers E, Liu J, Whitten J, Lim JK, Stopatschinskaja S, Hyman DM, Doebele RC, Cui JJ, Shaw AT. Drilon A, et al. Among authors: cui jj. Cancer Discov. 2018 Oct;8(10):1227-1236. doi: 10.1158/2159-8290.CD-18-0484. Epub 2018 Aug 9. Cancer Discov. 2018. PMID: 30093503 Free article.
Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Naïve and Solvent-Front-Mutant ROS1-Rearranged Non-Small Cell Lung Cancer.
Yun MR, Kim DH, Kim SY, Joo HS, Lee YW, Choi HM, Park CW, Heo SG, Kang HN, Lee SS, Schoenfeld AJ, Drilon A, Kang SG, Shim HS, Hong MH, Cui JJ, Kim HR, Cho BC. Yun MR, et al. Among authors: cui jj. Clin Cancer Res. 2020 Jul 1;26(13):3287-3295. doi: 10.1158/1078-0432.CCR-19-2777. Epub 2020 Apr 8. Clin Cancer Res. 2020. PMID: 32269053 Free article.
Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations.
Johnson TW, Richardson PF, Bailey S, Brooun A, Burke BJ, Collins MR, Cui JJ, Deal JG, Deng YL, Dinh D, Engstrom LD, He M, Hoffman J, Hoffman RL, Huang Q, Kania RS, Kath JC, Lam H, Lam JL, Le PT, Lingardo L, Liu W, McTigue M, Palmer CL, Sach NW, Smeal T, Smith GL, Stewart AE, Timofeevski S, Zhu H, Zhu J, Zou HY, Edwards MP. Johnson TW, et al. Among authors: cui jj. J Med Chem. 2014 Jun 12;57(11):4720-44. doi: 10.1021/jm500261q. Epub 2014 Jun 3. J Med Chem. 2014. PMID: 24819116
Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK).
Cui JJ, Tran-Dubé M, Shen H, Nambu M, Kung PP, Pairish M, Jia L, Meng J, Funk L, Botrous I, McTigue M, Grodsky N, Ryan K, Padrique E, Alton G, Timofeevski S, Yamazaki S, Li Q, Zou H, Christensen J, Mroczkowski B, Bender S, Kania RS, Edwards MP. Cui JJ, et al. J Med Chem. 2011 Sep 22;54(18):6342-63. doi: 10.1021/jm2007613. Epub 2011 Aug 18. J Med Chem. 2011. PMID: 21812414
199 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page